Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism

Contraception

Volumn 55, Issue 5, 1997, Pages 273-282

  Stanczyk, Frank Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

3 ketodesogestrel; Desogestrel; Ethinylestradiol; Gestodene; Metabolism; Norgestimate; Pharmacokinetics

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; ETONOGESTREL; GESTAGEN; GESTODENE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; REVIEW;

DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; KINETICS; NORGESTREL; NORPREGNENES; PROGESTERONE CONGENERS;

EID: 0030791647     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00030-9     Document Type: Review

References (38)

1. McGuire JL, Phillips A, Hahn DW, Tolman EL, Flor S, Kafrissen ME. Pharmacologic and pharmacokinetic characteristics of norgestimate. Am J Obstet Gynecol 1990;163:2127-31.
2. Alton KB, Hetyel NS, Shaw C, Patrick JE. Biotransformation of norgestimate in women. Contraception 1984; 29:19-29.
3. Chapdelaine A, Desmarais J-L, Derman AJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989;34:347-52.
4. Phillips A, Demarest K, Kahn DW, Wong F, McGuire JL. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990;41:339-410.
5. Juchem M, Pollow K, Elger W, Hoffmann G, Mobus V. Receptor binding of norgestimate - a new orally active synthetic progestational compound. Contraception 1994;47:255-63.
6. Jusko WJ. Bioavailability and pharmacokinetics of norgestimate following multiple-dose administration to healthy females. In preparation.
7. Kuhnz W, Blode H, Mahler M. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing oral contraceptive to 12 women. Contraception 1993;47:283-94.
8. Viinikka L. Radioimmunoassay of a new progestogen, ORG 2969, and its metabolite. J Steroid Biochem 1978; 9:979-82.
9. Viinikka L. Metabolism of a new synthetic progestogen, ORG 2969, by human liver in vitro. J Steroid Biochem 1979;10:353-7.
10. Hasenack HG, Bosch AMG, Kaar K. Serum levels of 3-ketodesogestrel after oral administration of desogestrel and 3-ketodesogestrel. Contraception 1986;33: 591-6.
11. Back DJ, Grimmer SFM, Shenoy N, Orme MLE. Plasma concentrations of 3-ketodesogestrel after oral administration of desogestrel and intravenous administration of 3-ketodesogestrel. Contraception 1987;35:619-26.
12. Orme M, Back DJ, Ward S, Green S. The pharmacokinetics of ethinylestradiol in the presence and absence of gestodene and desogestrel. Contraception 1991;43:305-16.
13. Fotherby K. Potency and pharmacokinetics of gestagens. Contraception 1990;41:533-50.
14. Tauber U, Tack JW, Matthes H. Single dose pharmacokinetics of gestodene in women after intravenous and oral administration. Contraception 1989;40:461-79.
15. Bergink W, Assendorp R, Kloosterboer L, van Lier W, Voortman G, Qvist I. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin. Am J Obstet Gynecol 1990;163:2132-7.
16. Kuhl H, Jung-Hoffmann C, Heidt F. Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception 1988;38:381-90.
17. Jung-Hoffmann C, Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception 1989;40: 299-312.
18. Kuhl H, Jung-Hoffmann C, Heidt F. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75 μg gestodene. Contraception 1988;38:477-486.
19. Dusterberg B, Tack J-W, Krause W, Humpel M. Pharmacokinetics and biotransformation of gestodene in man. In: Elstein M, ed. Gestodene, development of a new gestodene-containing low-dose oral contraceptive. Carnforth: Parthenon Publishers, 1986:35-44.
20. Kuhnz W. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and oral administration to women. Am J Obstet Gynecol 1990; 163:2120-7.
21. Pollow K, Juchem M, Grill NJ, et al. Gestodene: a novel synthetic progestin, characterization of binding to receptor and serum proteins. Contraception 1989;40:325-41.
22. Juchem M, Pollow K. Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol 1990;163:2171-83.
23. Phillips A, Hahn DW, McGuire JL. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin. Steroids 1990;55:373-5.
24. Guengerich FP. Mechanism-based III-A4 inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990;3:363-71.
25. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol 1990;163:2159-70.
26. Kuhnz W, Gansau C, Fuhrmeister A. Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one treatment cycle. Contraception 1992;46:29.
27. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188-215.
28. Report of the Working Group on Low-Dose Gestodene. Prepared by the McGill University Pharmacoepidemiology Collaborative Programme (Rapid Response Unit). McGill University, Montreal, Quebec, Canada, 1991.
29. Guengerich FP. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33:500-8.
30. Bocker R, Kleingerst B, Eichhorn M, Lepper, H. In vitro interaction of contraceptive steroids with human cytochrome P-450 enzymes. Adv Contracept 1991;7:140-8.
31. Back DJ, Houlgrave R, Tjia JF, Ward S, Orme L'E. Effect of the progestogens, gestodene, 3-ketodesogestrel, levonorgestrel, norethindrone and norgestimate on the oxidation of ethinylestradiol and other substrates by human liver microsomes. J Steroid Biochem Molec Biol 1991;38:219-25.
32. Humpel M, Tauber U, Kuhnz W, et al. Comparison of serum ethinylestradiol, sex-hormone binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. Hormone Res 1990;33:35-39.
33. Humpel M, Tauber U, Kuhnz W, et al. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and a single-dose ethinyl estradiol bioequivalence from both oral contraceptives. Am J Obstet Gynecol 1990;163:329.
34. Kuhnz W, Humpel M, Schutt B, Louton T, Steinberg B, Gansau C. Relative bioavailability of ethinylestradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design. Hormone Res 1990;33:40-4.
35. Dibbelt L, Knuppen R, Jutting G, Heimann S. Klipping CO, Parikka-Olexik H. Group comparison of serum ethinylestradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months. Contraception 1991;43:1-21.
36. Kuhnz W, Back D, Power J, Schutt B, Louton T. Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design. Hormone Res 1991;16:63.
37. Hammerstein J, Daume E, Simon A, et al. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2) on serum CBG and on urinary cortisol and 6β-hydroxycortisol. Contraception 1993;47: 263-81.
38. Bhavnani BR. Analytical methodology for estimation of ethinylestradiol following ingestion of oral contraceptives. Adv Contracep 1991;7:116-39.